ApicHope Pharmaceutical (300723) Fundamentals 2026 — P/E 81.8x, Revenue Analysis | SniperIQ
ApicHope Pharmaceutical (300723) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥16.3B, trading at ¥36.00 on the SHZ. This SniperIQ fundamentals page covers ApicHope Pharmaceutical's valuation (P/E 81.8x, P/B 8.4x), profitability (net margin 21.3%), revenue (¥932M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ApicHope Pharmaceutical's market cap?
ApicHope Pharmaceutical (300723) has a market capitalization of approximately ¥16.3B, trading at ¥36.00 on the SHZ. Market cap moves with the live share price.
What is ApicHope Pharmaceutical's P/E ratio?
ApicHope Pharmaceutical's trailing twelve-month P/E ratio is 81.8x, with a price-to-book (P/B) of 8.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ApicHope Pharmaceutical?
ApicHope Pharmaceutical runs a net profit margin of 21.3%, a gross margin of 58.6%, and an operating margin of 32.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ApicHope Pharmaceutical generate?
ApicHope Pharmaceutical reported revenue of ¥932M for fiscal year 2025, with net income of -¥338M and earnings per share (EPS) of -0.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ApicHope Pharmaceutical pay a dividend?
ApicHope Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ApicHope Pharmaceutical financially healthy?
ApicHope Pharmaceutical carries a debt-to-equity ratio of 1.04x and a current ratio of 1.45x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ApicHope Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ApicHope Pharmaceutical (300723) the key facts are: market cap ¥16.3B, P/E 81.8x, revenue ¥932M, 52-week range 29.31-81.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ApicHope Pharmaceutical's full fundamentals live
Get ApicHope Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.